Avid Bioservices Inc (CDMO)

[shipbuilder]

The PII NSCLC trial took place I. 2010, 2011, and 2012. The initial data presented from this trial was responsible for the jump in share price that, if you look at a chart that includes the last five years, happened in August and September of 2012. Shortly after that initial data was declared Peregrine released a PR that stated they had discovered discrepancies in the data and that the previously released information could not be relied upon. Again, reference the September 2012 chart to see the effect this PR had on share price.

I'm in a hurry, but the short of it is the 3 arm trial was marred by dose switching (intentional or not) between the placebo arm and the 1mg arm. The 3mg arm was unadulterated. Peregrine salvaged the data by combining both the 1mg arm and the placebo arm and calling that combination the control arm of the trial. They then compared the control against the 3mg arm and the result was still a 60% improvement in MOS over the (now boosted with 1mg of bavi in half the subjects) control arm. Basically it's old news.